

**USSN: 10/647,358 Filed on: 8-25-03**

Docket No.: 5790-C1-HMB

[Book Now](#) [View Details](#)

**INFORMATION DISCLOSURE CITATION**

*(Also several sheets if necessary)*

May 24 2012

**Number (Optional)** **5790-01-CA**

**Application Number**

09/485242

**Applicant(s)**  
**BISGAIER, CHARLES LARRY**

**Filing Date**

FEBRUARY 7, 2000

**Group Art Unit**

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
J	93/13801	07/22/1993	WO	—	—	✓	
J	0 738 510 A2	10/23/1996	EP	J	J		✓
J	97/14403	04/24/1997	WO	J	J	✓	
J	93/16690	09/02/1993	WO	—	—	✓	

**OTHER DOCUMENTS** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

		Glueck, et al, The American Journal of Card., "Gemfibrozil-Lovastatin Therapy for Primary Hyperlipoproteinemas" 1992, Vol. 70:1 PP. 1-9.
		Haag, et al, Cellular Singalling, "Lovastatin Inhibits Receptors-Stimulated Ca2+-Influx in Retinoic Acid Differentiated U937 and HL-60 Cells" 1994, Vol. 6:7; PP. 735-742
		Ramires, et al., Intern'l Journal of Card., "Effect of Gemfibrozil Versus Lovastatin on Increased Serum Lipoprotein(a) levels of patients with hypercholesterolemia", 1995, vol. 48:2; PP. 115-120.
		Dimitroulakos, et al., Nature Medicine, "HMG-CoA Reductase Mediates the Biological Effects of Retinoic Acid On Human Neuroblastoma Cells: Lovastatin Specifically Targets P-Glycoprotein-Expressing Cells" 1996, 2:3 PP. 326-333

**EXAMINER**

**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**USSN: 10/647,358**   **Fil d on: 8-25-03**  
**Docket No.: 5790-C1-HMB**

**O I P INFORMATION DISCLOSURE CITATION**  
*(Use several sheets if necessary)*

NOV 24 2003

Docket Number (Optional) <b>5790-01-CA</b>	Application Number <b>09/485242</b>
Applicant(s) <b>BISGAIER, CHARLES LARRY</b>	
Filing Date <b>FEBRUARY 7, 2000</b>	Group Art Unit

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS** (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	Ramharack, et al., Biochemical and Biophysical Research Comm., "Retinoids Inhibit Primary cynomolgus Monkey Hepatocyte Lipoprotein(a) Levels" 1997, Vol. 238:1, PP. 48-52
	Krause, et al., Expert Opinion on Investigational Drugs, "Emerging Therapies in Atherosclerosis", 1995, Vol. 4:5, PP. 353-387
	PCT International Serach Report, PCT/US98/23480

**EXAMINER**


**DATE CONSIDERED**

**EXAMINER:** Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**



Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/647,358
Filing Date				August 5, 2003	
First Named Inventor				Charles L. Bisgaier	
Group Art Unit				Not Yet Assigned	
Examiner Name				Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	5790-C1

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	6/64
-----------------------	---	--------------------	------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →  +

PTO/SB/08B (08-00)

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449B/PTO


## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet 2 of 2

Completion if Known	
Application Number	10/647,358
Filing Date	August 5, 2003
First Named Inventor	Charles L. Bisgaier
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	5790-CI

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Signature		Date Considered	6/04
--------------------	---	-----------------	------

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.  
**DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.